In the present study, we showed that the expression levels of the TGF-β signaling components, ALK5-FL and pSMAD2/3, neither were associated with clinicopathological parameters nor with the survival of non-ccRCC patients. The gene discussed is TGFB1; the disease is nonpapillary renal cell carcinoma.